Australia's most trusted
source of pharma news
Sunday, 21 April 2024
Posted 18 January 2022 AM
PBAC's latest public summary documents have revealed that reducing the cost of drugs was vital to getting a recommendation, but in some cases not enough.
Pfizer's Vyndamax for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) was not recommended. Pfizer reduced the ICER to $135,000 to <$155,000 QALY, from $155,000 to < $255,000 previously.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.